Dosing

DOSING CONSIDERATIONS

Vyxeos Liposomal is supplied in a single-dose vial containing 44 mg of daunorubicin and 100 mg of cytarabine1

  • Prior to initiating each cycle, calculate the prior cumulative anthracycline exposure for the patient
  • Assess cardiac function, complete blood counts, and liver and renal function before each consolidation cycle
  • Do not start consolidation until the absolute neutrophil count (ANC) recovers to greater than 500/μL and the platelet count recovers to greater than 50,000/μL in the absence of unacceptable toxicity
  • Administer the second consolidation cycle 5 to 8 weeks after the start of the first consolidation cycle in patients who do not show disease progression or unacceptable toxicity

References

  1. Vyxeos Liposomal – Summary of Product Characteristics, October 2019

 

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

INT-VYX-2000063 | June 2020